The Journal of Pediatrics of Korean Medicine (대한한방소아과학회지)

The Association of Korean Oriental Pediatrics (대한한방소아과학회)
권호 표지
DOI QR코드

DOI QR Code

Trend of Clinical Studies on Herbal Medicine Treatment for IgA Nephropathy in Children

소아 IgA 신병증의 한약 치료에 대한 임상연구 동향

  • Jeong, Jieun (Department of Pediatrics, College of Korean Medicine, Woosuk University) ;
  • Jeong, Minjeong (Department of Pediatrics, College of Korean Medicine, Woosuk University)
  • 정지은 (우석대학교 한의과대학 소아과학교실) ;
  • 정민정 (우석대학교 한의과대학 소아과학교실)
  • Received : 2022.07.29
  • Accepted : 2022.08.29
  • Published : 2022.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives The purpose of this study is to review relevant clinical studies to investigate the effectiveness of herbal medicines for IgA (Immunoglobulin A) nephropathy in children. Methods Studies on herbal treatment for IgA nephropathy were searched and analyzed through electronic databases such as PubMed, EMBASE, China National Knowledge Infrastructure, Wanfang, CiNii, J-STAGE, Oriental Medicine Advanced Searching Integrated System and Science ON. Studies included Randomized controlled trials and case series. Results We selected nine studies and analyzed the findings. In most studies, improvement of IgA nephropathy was observed after treatment, and was evaluated using factors as 24 hour urine protein, hematuria, Scr (serum creatinine) and BUN (blood urea nitrogen). The most commonly used herbs for IgA nephropathy were Poria cocos (茯苓), Astragalus membranaceus (黃芪), and Rehmannia glutinosa (生地黃). Conclusions Based on the results of the clinical studies, we identified that herbal medicine is an effective treatment for IgA nephropathy. However, additional systematic clinical studies are necessary to prove its effect and safety.

Keywords

References

  1. Berger J, Hinglais N. Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris). 1968;74(9):694-5.
  2. Hong CE. Textbook of pediatrics, 12th ed. Seoul: Miraen. 2020:109,1043-4.
  3. Jin GB, Kim JE, Yoon JS, Sung JH, Kwak JH, Whang EA, Han SY, Park SB, Kim HC. Long-term prognosis of IgA nephroapthy. Kidney Res Clin Pract. 2006;25(3):365-74.
  4. Berthoux FC, Mohey H, Afiani A. Natural history of primary IgA nephropathy. Semin Nephrol. 2008;28(1):4-9. https://doi.org/10.1016/j.semnephrol.2007.10.001
  5. Ping L, Yi-Zhi C, Hong-Li L, Zhao-Hui N, Yong-Li Z, Rong W, Hong-Tao Y, Jing-Ai F, Nian-Song W, Wen-Ge L, Xue-Feng S, Xiang-Mei C. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial. Trials. 2017;18(1):170. https://doi.org/10.1186/s13063-016-1774-6
  6. Zhong Y, Menon MC, Deng Y, Chen Y, He JC. Recent advances in traditional Chinese medicine for kidney disease. Am J Kidney Dis. 2015;66(3):513-22. https://doi.org/10.1053/j.ajkd.2015.04.013
  7. Kim JM, Kwon SW. Two case reports of renal failure induced by IgA nephropathy patients treated by Astragalus membranaceus. J Int Korean Med. 2014;381-6.
  8. Jeong JJ, Sun SH. End stage renal disease caused by IgA nephropathy: one case report. Korean J Oriental Physiology & Pathology. 2013;27(6):823-6.
  9. Chae EY, Chang SK, Cho CS, Kim CJ. The analysis about the course of clinical study on IgA nephropathy. Proc Daejeon Univ Inst Orient Med. 2006;15(2):273-82.
  10. Zheng X, Wang H, Ma K, Chen L, Miao C, Chen X. Effect of Huangkui capsule combined with mycophenolate mofetil on IgA nephropathy in children and its effect on serum BUN and SCR levels. Chin Arch of Tradit Chin Med [Internet]. Available from: https://kns.cnki.net/kcms/detail/21.1546.R.20220706.1825.048.html
  11. Zhou N, Shi X, Shen Y. The short-term therapeutic effects of TCM for IgA nephropathy in children. J Tradit Chin Med. 2011;31(2):115-9. https://doi.org/10.1016/S0254-6272(11)60024-1
  12. He Z. Observation of curative effect of 38 cases of children with primary IgA nephropathy treated with integrated traditional Chinese and western medicine. J Guangdong Med Coll. 2008;26(4):429-30.
  13. Wu R, Wang P, Shi Q, Yang X. Effect of Chungchoushenkang capsule on IgA nephropathy children's red blood cell immune function. J Clin Pediatr. 2002;20(12):744-5.
  14. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M. A prospective controlled study of Sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Jpn J Nephrol. 1997;39(5):503-6.
  15. Xu Z, Zhong G. Treatment of children with IgA nephropathy with Wulingsan and dipyridamole 29 cases. Chin Community Doct. 2011;13(31):176.
  16. Fu G, Wang Z. Treament of 54 cases of IgA nephrosis in children with "Yishen Liangxue Kangmin" decoction. Shanghai J Tradit Chin Med. 2006;40(7):54-5.
  17. Guo D, Xie H, Wang Y, Tan J, Han P. Treatment of IgA nephropathy in children by Shenyan Ning: A clinical observation of 25 cases. J New Chin Med. 2003;35(4):16-7.
  18. Li S. 15 cases of children with IgA nephropathy treated by enriching the kidney and activating blood. J New Chin Med. 2003;35(1):74
  19. Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, Katz AI. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol 1982;13(4):314-22. https://doi.org/10.1016/S0046-8177(82)80221-9
  20. Churg J, Sobin LH. Renal disease : Classification and atlas of glomerular diseases. 1st ed. New York: Igaku-Shoin Medical Pub. 1982:3-9.
  21. Liu H, Shi Z. Clinical study on the treatment of IgA nephropathy with Zishenhuayuqingli decoction. China J Tradit Chin Med Pharm. 1993;8(2):60.
  22. Zheng XY. Principle on instructing clinical research into new Chinese drugs. Beijing: China Medical Sci-tech Press. 2002;156-62.
  23. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64(245):709-27.
  24. Kim KB, Kim DG, Kim YH, Kim JH, Min SY, Park EJ, Baek JH, Sun HK, Yu SA, Lee SY, Lee JY, Chang GT, Jeong MJ, Chai JW, Cheon JH, Han YJ, Han JK. Hanbangsoacheongsonyeonuihak (ha). 2nd ed. Seoul: Eui Sung Dang Publishing Co. 2015:186-7.
  25. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38(4):728-35. https://doi.org/10.1053/ajkd.2001.27689
  26. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000;26(3):354-7. https://doi.org/10.1038/81677
  27. Hsu SI. Racial and genetic factors in IgA nephropathy. Semin Nephrol. 2008;28(1):48-57. https://doi.org/10.1016/j.semnephrol.2007.10.006
  28. Book Publishing Jeongdam Editorial Department. Integrative internal medicine: nephrology. 3rd ed. Seoul: Jeong Dam Publishing Co. 2016:172-8.
  29. Korean Society of Nephrology, Registry Committee. Renal Replacement Therapy in Korea. Kidney Res Clin Pract. 2006;25(S2):425-57.
  30. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM. Floege J. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1-S276. https://doi.org/10.1016/j.kint.2021.05.021
  31. Jeong HJ. Chronic cyclosporine nephrotoxicity in idiopathic nephrotic syndrome of childhood. Kidney Res Clin Pract. 2002;21(3).362-6.
  32. Chen XM, Chen YP, Zhou ZL. Prospective, multi-centered, randomized and controlled trialon effect of Shenle capsule in treating patients with IgA nephropathy of Fei-Pi qi-deficiency syndrome. Chin J Integr Med. 2006;26(12):1061-5.
  33. Chen XM, Chen YP, Chen J. Multicentered, randomized, controlled clinical trial on patients with IgA nephropathy of Qi-yin deficiency syndrome type. Chin J Integr Med. 2007;27(2):101-5.
  34. Li LT, Shi MY, Wei SY, Li T, Li B. Huai Qi Huang ameliorates proteinuria and hematuria in mild IgA nephropathy patients: a prospective randomized controlled study. J Formos Med Assoc. 2013;112(12):766-72. https://doi.org/10.1016/j.jfma.2013.10.019
  35. Yan P, Yao X, Ren C, Yin Z, Xie N, Wu L. Clinical observation of 100 cases of renal hematuria in children treated with Qingrelishuizhixue. Hebei J Traditional Chinese Medicine. 2015;37(5):695-7.
  36. Guo H, An J. Analysis of clinical efficacy of Qingrelishuizhixue in the treatment of children with renal hematuria. J Mod Med Health. 2017;33(13):2019-21.
  37. Han Z, Chang K, Chen J. Xinzhibaidihuang decoction treatment of children with renal hematuria by yin deficiency with effulgent fire 32 cases. Hebei J Traditional Chinese Medicine. 2011;33(12):1808-9.
  38. Meng X. Clinical observation on the treatment of children with renal hematuria by replenishing qi, tonifying the kidney, cooling the blood and resolving stasis. nei mongol journal of traditional chinese medicine. 2017;36(10):12.
  39. Bian Y, Qin M, Zhang T, Shang G, Zhong W, Zhang Y, Jin L, Shi W. The prescription characteristics of Qijibushenzhixue granules. Heilongjiang Journal of Traditional Chinese Medicine. 2014;43(6):68.
  40. Hu B, Zhang Y, Qin M. Treatment of 60 cases of asymptomatic hematuria in children with Qijibushenzhixue granules. Heilongjiang Journal of Traditional Chinese Medicine. 2014;43(4):8-9.
  41. Guan L. Children with renal hematuria treated by Yupingfeng powder 28 cases. Chinese and Foreign Medical Research. 2012;10(19):134-5.
  42. Li H. Clinical observation of 100 cases of IgA nephropathy and hematuria treated with Guipi decoction combined with western medicine. China Medical Herald. 2011;8(6):82-3.
  43. Ji Y, Cao M, Yang L, Xiang L, Chen Z, Zhao X, Nie X, Luo R. Research progress in diagnosis and treatment of IgA nephropathy with integrated traditional Chinese and western medicine. Liaoning J Traditional Chinese Medicine. 2018;45(4):872-4.
  44. Hattori T, Sadakane C, Koseki J, Kase Y, Takeda S. Saireito probably prevents mesangial cell proliferation in HIGA mice via PDGF-BB tyrosine kinase inhibition. Clinical and Experimental Nephrology. 2007;11(4):275-82. https://doi.org/10.1007/s10157-007-0493-4
  45. Kimura K, Nanba S, Tojo A, Matsuoka H, Sugimoto T. Effects of sairei-to on the relapse of steroid-dependent nephrotic syndrome. Am J Chin Med. 1990;18:45-50. https://doi.org/10.1142/S0192415X90000071
  46. Liu XY. Therapeutic effect of chai-ling-tant (sairei-to) on the steroid-dependent nephrotic syndrome in children. Am J Chin Med. 1995;23:255-60. https://doi.org/10.1142/S0192415X95000304
  47. Zhang L. Efficacy analysis of Chailing decoction in patients with chronic glomerulonephritis. Modern Diagnosis & Treatment. 2017;28(3):432-3.
  48. An SY. Herbal treatment of kidney disease in children. Korea School Health Association. 2004;42-9.
  49. Kim IR, Kim HC, Kuk YB, Park SJ, Park YG, Park JH, Seo BI, Seo YB, Song HJ, Lee YJ, Lee YC, Lee JH, Lim GH, Jo SI, Jung JG, Joo YS, Choi HY. Bonchohak. 3rd ed. Seoul: Young Lim Publishing Co. 2013:232, 346, 578.
  50. Zan JF, Shen CJ, Zhang LP, Liu YW. Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome. Chin J Integr Med. 2017;23(12):916-22. https://doi.org/10.1007/s11655-016-2643-6
  51. Lee SM, Lee YJ, Yoon JJ, Kang DG, Lee HS. Effect of Poria cocos on puromycin aminonucleoside-induced nephrotic syndrome in rats. Evid Based Complement Alternat Med. 2014;2014:1-12.
  52. Zhao YY, Feng YL, Bai X, Tan XJ, Lin RC, Mei Q. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. PLoS One. 2013;8(3):1-10.
  53. Zhong Q. Clinical Experience of professor Chen Xianji in treating IgA nephropathy. Chinese Journal of Integrated Traditional and Western Nephrology. 2004;5(4):189-90.
  54. Luo W. Analysis of 60 cases of IgA nephropathy treated by Buqigushentongluo. Journal of Practical Traditional Chinese Internal Medicine. 2003;17(5):411-2.
  55. Song Y, Zhang X. Clinical observation on dual deficiency of qi and yin type IgA nephropathy by replenishing qi and tonifying the kidney. Chinese Journal of Integrated Traditional and Western Nephrology. 2003;4(12):732-3.
  56. Li M, Wang W, Xue J, Gu Y, Lin S. Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy. J Ethno pharmacol. 2011;133(2):412-9.
  57. Zhang J, Xie X, Li C, Fu P. Systematic review of the renal protective effect of Astragalus membranaceus (root) on diabetic nephropathy in animal models. J Ethnopharmacol. 2009;126(2):189-96. https://doi.org/10.1016/j.jep.2009.08.046
  58. Li SM, Yan JX, Yang L. Effects of Astragalus injection on renal tubular function in patients with IgA nephropathy. Chin J Integr Traditional and Western Med. 2006;26(6):504-7.
  59. Peng XJ, Wu XC, Zhang GZ, Yi ZW, Zheng WM, He XJ, Mo SH, Tan H. Regulatory effect of Astragalus membranaceus on the immune disorder in rats with IgA nephropathy. Chinese journal of pediatrics. 2008;46(1):55-60.
  60. Lu D, Li W, Liu Z, Qin R, Liang A, Lu T. Research progress of traditional Chinese medicine in the treatment of hematuria in children with IgA nephropathy in recent 10 years. Popular Science & Technology. 2021;23(11):80-2.
  61. Choe JB, Kim YS, Han YH. The effects of Rehmannia on nephrectomy-induced chronic renal failure rats. Korean J Orient Int Med. 2008;29(4):1100-14.
  62. Lee KH, Choi JB, Kim YS, Cho SI. Anti-oxidative effects of Radix rehmanniae recens and preparata on toxic agent induced kidney cell injury. Korean J Orient Int Med. 2003;24(3):522-30.
  63. Park JB, Kim KS. Effects of Rehmannia glutinosa aqua-acupuncture at the meridian ponits BL 23 on the renel function in two-kidney one clip goldblatt hypertensive rats. J Korean Acupunct Moxib Soc. 1994;11(1):225-39.